POPLAR: 3-year survival and duration of response data
In the 3-year-survival analysis of the phase II study POPLAR atezolizumab demonstrated superior 2-year and 3-year overall survival (OS) benefit compared with docetaxel in patients with advanced NSCLC. This benefit was observed across histology and PD-L1 expression subgroups (including TC0 and IC0). Atezolizumab was well tolerated, and responses were highly durable. These results are consistent with long-term OS results from the phase III study OAK.
The 2-year and 3-year survival with atezolizumab (1200 mg) vs docetaxel (75 mg/m²) IV y3w were 32.2% vs 16.6% and 18.7% vs 10.0%, respectively. The long-term OS benefit of atezolizumab vs docetaxel was observed across histology and PD-L1 expression subgroups. While the TC3 or IC3 subgroup derived the greatest OS benefit, the TC0 and IC0 subgroup also had improved long-term OS with atezolizumab vs docetaxel. The ITT ORR was 15 % in both atezolizumab and docetaxel arms, but the median duration of response was 3 times longer with atezolizumab (22.3 months [95 % CI: 11.6, 31.1] vs 7.2 months [95 % CI: 5.8, 12.2] with docetaxel). Seven of the 11 docetaxel-arm 3-year survivors received subsequent non-protocol therapy with anti–PD-L1/PD-1 agents. Atezolizumab had a favourable safety profile compared with docetaxel that was consistent with previous reports.
Um den Beitrag in voller Länge zu lesen, müssen Sie sich einloggen oder kostenlos registrieren.
Ihre Vorteile auf medonline.at
- Personalisierte Inhalte auf Ihr Profil zugeschnitten
- DFP Fortbildung: e-Learnings, Literaturstudien & MM-Kurse
- Aktuelle Fachartikel, State-of-the-Art-Beiträge, Kongressberichte, Experteninterviews
Registrieren Sie sich jetzt kostenlos & bleiben Sie top-informiert!